dexamethasone NDC 60219-2043

NDC codes

FDA NDC Directory

Product NDC (as listed)60219-2043Labeler and product segments. Claims need a package NDC.

Product NDC at billing width60219-2043Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
60219-2043-1	60219204301	100 TABLET in 1 BOTTLE, PLASTIC (60219-2043-1)Marketed from Sep 1, 2021

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): dexamethasone
Generic name (nonproprietary): dexamethasone
Active ingredients: Dexamethasone — 4 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Amneal Pharmaceuticals NY LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 215106
Marketing start: Sep 1, 2021
Listing expires: Dec 31, 2026
Other FDA classes: Corticosteroid Hormone Receptor Agonists (Mechanism)
Identifiers: Product ID 60219-2043_574d26cb-6ade-4619-be52-ef855081c8daSPL ID 574d26cb-6ade-4619-be52-ef855081c8daSPL set ID ac71f888-c83a-46a5-921c-1ebdf6cfadc1RxCUI 197582, 197583UNII 7S5I7G3JQLUPC 0360219204317
Pharmacologic class: Corticosteroid

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N460219204301 followed by a unit qualifier and the quantity

Package 60219-2043-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 21, 2024.

Indications (excerpt from the label)

INDICATIONS AND USAGE Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocortico…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 215106

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 215106
Product	Strength	Form · route	Labeler	Product NDC
dexamethasone	Dexamethasone 4 mg/1	TabletOral	Cardinal Health 107, LLC	55154-4315
dexamethasone	Dexamethasone 4 mg/1	TabletOral	Major Pharmaceuticals	0904-7266
dexamethasone	Dexamethasone 6 mg/1	TabletOral	Major Pharmaceuticals	0904-7267
dexamethasone	Dexamethasone 6 mg/1	TabletOral	Preferred Pharmaceuticals Inc.	68788-8293
dexamethasone	Dexamethasone 6 mg/1	TabletOral	Amneal Pharmaceuticals NY LLC	60219-2044